Every three minutes a patient is diagnosed with a blood cancer in the US.1 Developing effective treatments to battle these blood-based malignancies is a primary focus for Novella, and we are proud that this work comprises nearly one third of Novella’s overall oncology clinical trial portfolio. We believe hematologic oncology trials are fundamentally different from solid tumor studies due to their complex disease assessments and lab-based endpoints, and have thus built hematology/oncology specialty teams within our Oncology Division to hire staff and build solutions specifically for these types of trials.
Starting with trial design, case report forms and selection of both primary and surrogate endpoints, our team works with customers to ensure meaningful and measurable data are captured and reported. We follow with data management and biostatistics professionals who are trained in hematologic disorders, and recognize challenges common within hematology patients, including abnormal lab values or neutropenia.
Our relationships with key hematology sites and investigators allow us to help guide customers in effective site selection based on the program, taking disease incidence, patient experience, and any protocol-defined genetic selection needs into account.
Hematology Oncology Trial Experience
- Acute Myeloid Leukemia (AML)
- Chronic Myelogenous Leukemia (CML)
- Non-Hodgkin Lymphoma (NHL)
- Myelodysplastic Syndrome (MDS)
- Multiple Myeloma (MM)
- Rare hematologic malignancies (e.g., ALL, CLL, CTCL, PTCL, DLBCL)
Contact us to learn how Novella can advance your hematologic drug development program.
1. The Leukemia & Lymphoma Society, Facts and Statistics. http://www.lls.org/facts-and-statistics/facts-and-statistics-overview